ReviewBone reports2019
Positive and negative regulators of osteoclast apoptosis.
Review in Bone reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Associations between hormones, metabolic markers, and bone mass in perimenopausal and postmenopausal women.Journal of bone and mineral metabolism · 2025Article
- Bone marrow adipogenic lineage precursors are the major regulator of bone resorption in adult mice.Bone research · 2025Article
- Osteoclast-derived apoptotic bodies accelerate the pathological progression of osteoarthritis via disturbing subchondral bone remodeling.Journal of orthopaedic translation · 2025Article
- Biomaterial Cues for Regulation of Osteoclast Differentiation and Function in Bone Regeneration.Advanced therapeutics · 2025Article
- Association between radiographic equine distal phalanx characteristics and absence, presence and type of horseshoes.Frontiers in veterinary science · 2025Article
- Bone marrow adipogenic lineage precursors are the major regulator of bone resorption in adult mice.Research square · 2024Article
- The bone nonunion microenvironment: A place where osteogenesis struggles with osteoclastic capacity.Heliyon · 2024Review
- Article
- Nutraceuticals in osteoporosis prevention.Frontiers in nutrition · 2024Review
- Anti-osteoporotic effects of Yi Mai Jian on bone metabolism of ovariectomized rats.Frontiers in pharmacology · 2024Article
- Functional and analytical recapitulation of osteoclast biology on demineralized bone paper.Nature communications · 2023Article
- Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation.Current osteoporosis reports · 2022Review
- Advances in the Therapeutic Effects of Apoptotic Bodies on Systemic Diseases.International journal of molecular sciences · 2022Review
- The Effect of Osteoblast Isolation Methods from Adult Rats on Osteoclastogenesis in Co-Cultures.International journal of molecular sciences · 2022Article
- Protein tyrosine phosphatases in skeletal development and diseases.Bone research · 2022Review
- Traditional Chinese decoction Si Zhi Wan attenuates ovariectomy (OVX)-induced bone loss by inhibiting osteoclastogenesis and promoting apoptosis of mature osteoclasts.Frontiers in pharmacology · 2022Article
- Article
- How zoledronic acid improves osteoporosis by acting on osteoclasts.Frontiers in pharmacology · 2022Review
- New Insights Into Osteoclast Biology.JBMR plus · 2021Review
- Osteoclast Fusion: Physiological Regulation of Multinucleation through Heterogeneity-Potential Implications for Drug Sensitivity.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survival and apoptosis are of major importance in the osteoclast life cycle. As osteoclasts have short lifespan, any alteration that prolongs their viability may cause enhanced osteoclast activity. Hence, the regulation of OC apoptosis has been recognized as a critical factor in bone remodeling. An imbalance in bone remodeling due to increased osteoclast activity leads to most adult bone diseases such as osteoporosis, rheumatoid arthritis and multiple myeloma. Therefore, manipulating osteoclast death would be a viable therapeutic approach in ameliorating bone diseases, with accelerated resorption. Over the last few decades we have witnessed the unraveling of many of the intracellular mechanisms responsible for osteoclast apoptosis. Thus, an understanding of the underlying mechanisms by which osteoclasts undergo programmed cell death and the regulators that modulate that activity will undoubtedly provide an insight into the development of pharmacological agents to treat such pathological bone diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.